To Assess the Pharmacokinetics and Safety and Tolerability of Efanesoctocog Alfa (BIVV001)in Adults With Type 2N and 3 Von Willebrand Disease (VWD)

Inclusion criteria : \-- Male and/or female participant, between 18 and 65 years of age, inclusive at the time of informed consent. * The participant has been diagnosed with hereditary type 3 VWD or type 2N VWD as documented in historical medical records OR a documented genotype known to produce VWD type 3 or 2N VWD. * Type 3 VWD participants are included if they have a medical history of at least 25 exposure days to VWF and factor VIII-containing coagulation factor concentrates * Type 2N VWD participants are included if the use of DDAVP is deemed insufficient or contraindicated, as assessed by the Investigator, or if they have required prior use of VWF- and FVIII- containing coagulation factor concentrates. Exclusion criteria: * Hereditary or acquired coagulation disorder other than VWD (including qualitative and quantitative platelet disorders, and thrombocytopenia \< 100,000 cells/uL at Screening) * The participant has a FVIII activity levels \>20 IU/dL, at Screening * History or presence of a VWF inhibitor or clinical suspicion of a VWF inhibitor * History of a positive FVIII inhibitor test, defined as ≥0.6 BU/mL (by Nijmegen modified Bethesda assay) or a clinical suspicion of a FVIII inhibitor * Positive FVIII inhibitor test, defined as ≥0.6 BU/mL, at Screening * History of hypersensitivity or anaphylaxis associated with any FVIII- or VWF- containing product * The participant has received or anticipates receiving systemic immunosuppressive or immunomodulatory treatme…